Global Leading Market Research Publisher QYResearch announces the release of its latest report “Adventitious Agent Detection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Adventitious Agent Detection market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Adventitious Agent Detection was estimated to be worth US$ 3808 million in 2025 and is projected to reach US$ 5966 million, growing at a CAGR of 6.7% from 2026 to 2032.
Adventitious Agent Detection (AAD) refers to the process of testing biological products, cell cultures, or raw materials for unintended contaminants, such as viruses, bacteria, mycoplasma, fungi, or other microbial agents, that may have been introduced unintentionally during production, handling, or storage. The goal is to ensure product safety, purity, and regulatory compliance in biopharmaceuticals, vaccines, and cell/gene therapy products.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096911/adventitious-agent-detection
1. Industry Pain Points and the Shift Toward Comprehensive Viral Safety Testing
Biologics—monoclonal antibodies, vaccines, cell and gene therapies—are produced in living cells (CHO, HEK293, microbial systems), creating inherent risk of contamination by adventitious agents (viruses, mycoplasma, bacteria, fungi). A single undetected contaminant can cause product recalls, patient infections, or clinical trial failures. Adventitious agent detection addresses this through in vitro (cell culture assays, PCR, NGS) and in vivo (animal inoculation) methods to ensure viral safety testing, mycoplasma detection, and biologics contamination control. For biopharmaceutical manufacturers and CDMOs, these tests are mandatory for regulatory compliance (FDA, EMA, ICH Q5A) and patient safety.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global adventitious agent detection market was valued at US$ 3.808 billion in 2025 and is projected to reach US$ 5.966 billion by 2032, growing at a CAGR of 6.7%. Market growth is driven by three factors: expanding cell and gene therapy pipeline (requiring extensive viral safety testing), increasing regulatory scrutiny following high-profile contamination events (Genzyme, Amgen), and adoption of next-generation sequencing (NGS) for broad-spectrum detection.
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four notable developments:
- NGS for adventitious virus detection: FDA and EMA guidance (2025) endorsed NGS as alternative to in vivo assays, reducing testing time from months to weeks. NGS segment grew 30% year-over-year.
- Cell therapy manufacturing expansion: CAR-T and stem cell therapies require extensive mycoplasma and virus testing at multiple stages. Cell therapy segment grew 20% in 2025.
- Outsourcing trend: Biopharma companies outsourced 70% of AAD testing to CROs (Charles River, BioReliance, Labcorp, Sartorius, KBI) to avoid capital investment. Outsourcing segment grew 15% year-over-year.
- Chinese CRO emergence: Clean Biologics and Syngene International (India) expanded AAD capacity, capturing Asia-Pacific market share at 20-30% below Western pricing.
4. Competitive Landscape and Key Suppliers
The market includes global CROs and specialized AAD laboratories:
- BioReliance (US – Merck KGaA), Clean Cells (France), Charles River Laboratories (US), Intertek (UK), KBI Biopharma (US), Labcorp Drug Development (US), PathoQuest (France), Sartorius BioOutsource (UK), Syngene International (India), ViruSure (Austria), Clean Biologics (China).
Competition centers on three axes: detection breadth (virus panel size), turnaround time (weeks to days), and regulatory expertise (FDA/EMA).
5. Segment-by-Segment Analysis: Type and Application
By Detection Method
- In Vitro Adventitious Agent Detection: Largest segment (~70% of market). Cell culture assays (MAP, HAP, RAP), PCR (mycoplasma), NGS (broad-spectrum virus detection). Faster, lower cost, reduced animal use.
- In Vivo Adventitious Agent Detection: (~30% of market). Animal inoculation (suckling mice, adult mice, embryonated eggs). Declining due to 3R principles (Replacement, Reduction, Refinement). Required for some regulatory submissions.
By End User
- Biopharmaceuticals: Largest segment (~70% of market). mAbs, recombinant proteins, vaccines.
- Hospital: (~15% of market). Cell therapy release testing (CAR-T, stem cells).
- Others: Academic research, CDMOs. ~15% of market.
User case – CHO cell bank viral safety (mAb manufacturer) : A mAb manufacturer outsourced adventitious agent testing (BioReliance) for CHO master cell bank. Tests included in vitro (MAP, HAP, RAP, mycoplasma, NGS) and in vivo (mouse, egg). All tests negative, enabling IND filing. NGS detected a previously unknown endogenous retrovirus-like sequence (non-infectious), documented for regulatory transparency.
6. Exclusive Insight: Adventitious Agent Detection Methods
| Method | Detection Targets | Turnaround | Sensitivity | Regulatory Acceptance |
|---|---|---|---|---|
| In vitro (cell culture) | Viruses (MAP, HAP, RAP) | 28-56 days | Moderate | Full (FDA, EMA) |
| Mycoplasma PCR | Mycoplasma | 1-3 days | High (10 CFU/mL) | Full (EP 2.6.7, JP) |
| Mycoplasma culture | Mycoplasma | 28 days | High | Full (FDA) |
| NGS (next-gen sequencing) | Broad-spectrum viruses | 7-14 days | Very high | Emerging (FDA, EMA guidance) |
| In vivo (animal) | Viruses, adventitious agents | 28-56 days | Moderate | Full (FDA, EMA) |
Technical challenge: Detecting unknown or novel viruses (not targeted by specific PCR assays). NGS addresses this by sequencing all nucleic acids in the sample, comparing to viral databases. However, NGS cannot distinguish infectious from non-infectious viral sequences. Confirmatory assays (cell culture, infectivity) still required for positive NGS results.
User case – Novel virus detection by NGS: A gene therapy manufacturer tested HEK293 cell banks by NGS (PathoQuest). NGS detected a novel parvovirus-like sequence not previously described. Follow-up testing (PCR, electron microscopy) confirmed non-infectious endogenous sequence. FDA accepted NGS data as part of safety package, avoiding additional in vivo testing.
7. Regional Outlook and Strategic Recommendations
- North America: Largest market (45% share, CAGR 6.5%). US (BioReliance, Charles River, Labcorp, KBI). Strong cell and gene therapy pipeline.
- Europe: Second-largest (30% share, CAGR 6.5%). France (Clean Cells, PathoQuest), UK (Intertek, Sartorius), Austria (ViruSure). Strong regulatory framework.
- Asia-Pacific: Fastest-growing region (CAGR 7.5%). China (Clean Biologics), India (Syngene). Cost-effective CRO services.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The adventitious agent detection market is positioned for strong growth through 2032, driven by cell and gene therapy expansion, regulatory requirements, and NGS adoption. Stakeholders—from biopharma companies to CROs—should prioritize NGS for broad-spectrum virus detection, in vitro methods for regulatory compliance, and mycoplasma PCR for rapid release testing. By enabling viral safety testing and biologics contamination control, adventitious agent detection is essential for patient safety and product quality.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
